|
|
Welcome to
the ISOPP Website
Thanks to our Sponsors
EMEA positive opinion for azacitidine
By: Felice Musicco
on: Wed 19 of Nov, 2008 [12:00 UTC]
(0 reads)
|
|
The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for Vidaza (azacitidine), from Celgene Europe Ltd, for the treatment of myelodysplastic syndromes and acute myeloid leukaemia in adults who are not eligible for haematopoietic stem-cell transplantation. Vidaza is the 50th orphan medicine to receive a positive opinion by the CHMP.
|
Researchers discover new way to attack some forms of leucemia
By: Felice Musicco
on: Mon 17 of Nov, 2008 [10:56 UTC]
(10 reads)
|
|
News from the American Society for Biochemistry and Molecular Biology website. The research was recently published online in the prestigious Journal of Biological Chemistry of the American Society for Biochemistry and Molecular Biology, and is forthcoming in the print edition.
News received by Rolando Moroni
|
FDA: Update Regarding Atrial Fibrillation With Bisphosphonates
By: Felice Musicco
on: Fri 14 of Nov, 2008 [19:24 UTC]
(22 reads)
|
|
FDA Medwatch issued an update about the Agency's review of safety data regarding the potential increased risk of atrial fibrillation in patients treated with a bisphosphonate drug.
|
Three new NCCN guidelines: colon cancer, anal carcinoma, rectal cancer
By: Felice Musicco
on: Thu 13 of Nov, 2008 [10:41 UTC]
(29 reads)
|
|
"The NCCN (National Comprehensive Cancer Network) now requires that all users of NCCN content register to access the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs and Biologics Compendium™, and the NCCN Chemotherapy Order Templates™"
News received by Rolando Moroni
|
Member Discussions Page - current topics being discussed
By: Felice Musicco
on: Tue 11 of Nov, 2008 [12:59 UTC]
(38 reads)
|
|
ISOPP Members can access a discussion area to ask or answer questions, or set up discussion on a topic.
|
EMEA Extensions of indication for cetuximab
By: Felice Musicco
on: Sun 09 of Nov, 2008 [11:55 UTC]
(42 reads)
|
|
The CHMP gave positive opinions for applications for extension of indication, adding new treatment options for Erbitux (cetuximab), from Merck KGaA, to extend the indication to the treatment of patients with squamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
|
New SIGN guideline: Control pain in adults with cancer
By: Felice Musicco
on: Fri 07 of Nov, 2008 [10:33 UTC]
(56 reads)
|
|
"SIGN (Scottish Intercollegiate Guidelines Network) has a programme of 113 evidence-based clinical guidelines - published, in development, or under review - covering a wide range of topics. Many of the SIGN guidelines relate to the NHS priority areas of cancer, cardiovascular disease, and mental health. Comments on any of the published guidelines are welcome and will be used to inform the review process. "
News received by Rolando Moroni
|
ISMP: A Near Miss Involving Cyclophosphamide
By: Felice Musicco
on: Wed 05 of Nov, 2008 [06:44 UTC]
(85 reads)
|
|
"Reports of near-miss incidents offer valuable learning opportunities. This bulletin highlights a near miss with cyclophosphamide for intravenous administration, with the goal of sharing learning and recommendations related to the use of cytotoxic medications for non-oncology indications."
The Institute for Safe Medication Practices Canada acknowledges Larry Broadfield, Past President of ISOPP.
News received by Jill Davis
|
WHO Pharmaceuticals Newsletter n. 3 /2008
By: Felice Musicco
on: Mon 03 of Nov, 2008 [13:05 UTC]
(79 reads)
|
|
"The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of "drug information officers" and other sources such as specialized bulletins and journals. The information is produced in the form of résumés in English."
News received by Johan Vandenbroucke
|
WHO's Medium Term Strategic Plan for 2008-2013
By: Felice Musicco
on: Sat 01 of Nov, 2008 [09:42 UTC]
(65 reads)
|
|
Over the last decade, WHO's activities in the field of medicines have been guided by the WHO Medicines Strategies for 2000-2003 and 2004-2007. Based on these good experiences and to ensure a strong foundation for the 'new' Department of Essential Medicines and Pharmaceutical Policies, WHO has decided to develop a third Medicines Strategy to formulate strategic approaches within the scope of WHO's Medium Term Strategic Plan for 2008-2013.
|
|
ISOPP HOPA 2008
Click on the Logo above to link to the ISOPP/HOPA
symposium page
|
